Cantor Fitzgerald's Elemer Piros initiated Aerie Pharmaceuticals AERI at Buy with a price target of $44.00.
"Aerie could dominate the glaucoma market with drugs that have novel mechanisms of action" said Piros.
Glaucoma is a disease that is popular in the United States, but has not seen any approved innovation in the drug treatment market for over two decades. According to the analyst, 3.5 million Americans have Glaucoma and "no new agents have been approved for 20 years."
Market News and Data brought to you by Benzinga APIsLikely Takeover Candidate
Sales from Aerie's Rhopressa and Roclatan drugs could approach $1.5 billion with a 8-12 percent market penetration. "Based on this we would not be surprised if Aerie became a takeover candidate upon successful achievement of regulatory milestones or perhaps even before" said Piros. At the time of writing, Aerie Pharmaceuticals was trading up 7.56 percent at $19.06.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in